Jeffrey P. Beckenbaugh, DO






In This Edition

Peri-operative Dexamethasone for Control of Pain After Total Knee Arthroplasty

Indirect reduction and fixation of a Lateral Plateau depression fracture utilizing balloon tibioplasty in a cachectic, malnourished patient: A Case Report

Please Join Us at the Postgraduate Seminar

2012 Annual Meeting Recap

Changes Coming to the 2013 Annual Meeting

AOA Develops New Platform for Posting CME Credits for 2013-2015 Cycle

New FDA Ruling Prompts Added CME Option for Providers

Physician Payment Sunshine Act: Final Rule

Good Samaritan Regional Medical Center Orthopedic Surgery Residency Program in its Third Year

We Need More Doctors in Government - How About You?

SAOAO Report:
Student AOAO - A Glance at the Past and a Spotlight on the Future

RAOAO Report

Member Spotlight: Steven J. Heithoff, DO, FAOAO

Thank you to our preliminary exhibitors and supporters

Gold Level
DePuy Orthopaedics

Silver Level
Auxilium Pharmaceuticals
Innomed, Inc.
Smith & Nephew

Bronze Level
Biomet Orthopaedics

American Osteopathic Board of Orthopedic Surgery
Auxilium Pharmaceuticals
BioMarin Pharmaceutical Inc.
Biomet Orthopaedics
BioPro, Inc
ConforMIS, Inc.
DePuy Orthopaedics
Elsevier USA
Innomed, Inc.
Lippincott, Williams & Wilkins
Skeletal Dynamics
Smith & Nephew
The Progressive Orthopaedic Company
Wright Medical Technology, Inc.

Commercial Support
AOAO would like to thank the following companies for providing an educational grant:

DePuy Synthes USA

For the up-to-date list of exhibitors and products descriptions, click here.

Physician Payment Sunshine Act: Final Rule

Taken from AOA CME E-Newsletter

On Friday, Feb. 1, the Centers for Medicare and Medicaid Services (CMS) released its “Final Rule” implementing the Physician Payment Sunshine Act. The Final Rule is 286 pages and was published in the Federal Register on Friday, Feb. 8.

The Sunshine Act includes several exceptions from the disclosure requirements, including, for example, payments to a physician or a teaching hospital in amounts under $10 (amount increases annually based on Consumer Price Index) so long as annual aggregate payments do not exceed $100; educational materials and samples used by patients; discounts and rebates; and payments for speaking at accredited or certified CME programs. While the definition of “applicable manufacturer” is broad under the Final Rule, hospitals, hospital-based pharmacies and labs that manufacture products solely for internal use or for patients do not qualify as “applicable manufacturers” for purposes of the Sunshine Act.

The Final Rule also sets forth several important upcoming dates. Manufacturers and GPOs must begin to collect data on Aug. 1, 2013. They must track data between Aug. 1, 2013 and Dec. 31, 2013 and report this data to CMS by March 31, 2014. Data will be submitted via an electronic system to be published by CMS at a later date.

The Final Rule includes several penalties for non-compliance with the Sunshine Act. Applicable manufacturers and GPOs that fail to report as required by the Final Rule can be subject to a civil monetary penalty (CMP) of up to $150,000 annually, and intentional failures to report carry much stricter penalties, up to $1,000,000. CMS has also reserved the right to review compliance by applicable manufacturers and GPOs, and these entities are now required to maintain records and documents for at least five (5) years from the date of publication of the reportable event.

For more information about the Sunshine Act and the Final Rule, CMS has distributed a fact sheet.

Back to top